Bicycle Therapeutics plc focuses on an innovative class of fully synthetic two-loop peptides called Bicycle® molecules, which aim to combine biologic-like target affinity with small molecule manufacturing efficiency. Despite no product revenues to date and mounting operating losses, the company’s growing pipeline—anchored by clinical-stage oncology candidates nuzefatide pevedotin and zelenectide pevedotin—demonstrates potential for addressing high unmet medical needs. The firm maintains a robust cash position from recent equity raises, providing runway amid ongoing R&D investment, while navigating significant regulatory and clinical risks. Strong cybersecurity oversight reflects operational diligence critical for protecting intellectual property and clinical data integrity.